水合2-氯乙醛 | 65703-76-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 中文名称: 水合2-氯乙醛
• 英文名称: chloroacetaldehyde monohydrate
• 英文别名: chloroacetaldehyde hydrate；2-chloroacetaldehyde;hydrate
• CAS: 65703-76-6
• 化学式: C₂H₃ClO*H₂O
• 分子量: 96.5135
• InChiKey: SUQCVWYRTYMULT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-二氨基-5-溴吡啶 、 水合2-氯乙醛 以 异丙醇 为溶剂， 反应 24.0h， 以to afford 9.10 g of product的产率得到6-溴-1H-咪唑并[1,2-a]吡啶-8-胺
  参考文献：
  名称：

  Inhibitors of bruton's tyrosine kinase

  摘要：

  本申请披露了新的咪唑[1,2-a]吡啶和咪唑[1,2-b]吡嗪衍生物，其按照式I-VI定义：其中R、R'、R"、Q、X和Y如本文所述，可以抑制Btk。本文披露的化合物有助于调节Btk的活性并治疗与过度Btk活性相关的疾病。这些化合物还有助于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，例如类风湿性关节炎。本申请还披露了含有式I-VI化合物和至少一种载体、稀释剂或赋形剂的组合物。

  公开号：

  US08426441B2

文献信息

• 2-oxoazetidin-1-yloxy acetic acids and analogs
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04939253A1

  公开（公告）日：1990-07-03

  Antibiotic activity is exhibited by .beta.-lactams having an ##STR1## substituent (and analogs thereof) in the 1-position and an acylamino substituent in the 3-position.

  β-内酰胺类抗生素在1-位置具有##STR1##取代基（及其类似物），在3-位置具有酰氨基取代基时表现出抗生素活性。
• Novel 3-amino-2-oxo-azetidine-1-sulfonic acids
  申请人：Roussel Uclaf

  公开号：US04900728A1

  公开（公告）日：1990-02-13

  Novel syn isomers of racemates and optical isomers of 3-amino-2-oxo-azetidine-1-sulfonic acids of the formula ##STR1## wherein R is selected from the group consisting of hydrogen linear or branched optionally substituted alkyl of 1 to 12 carbon atoms and optionally substituted alkenyl and alkynyl of 2 to 12 carbon atoms, R.sub.1 is --(CH.sub.2).sub.n --X, n is an integer from 1 to 4, X is selected from the group consisting of halogen, --CN, --OR', --SR.sub.1 ", azido, thiocyanate, isothiocyanate, and ##STR2## is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R" is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and a heterocycle and R' and R" are individiually selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms and taken together with the nitrogen to which they are attached form a heterocycle and A.sup.1 is selected from the group consisting of hydrogen, and metal cations and their nontoxic, pharmaceutically acceptable acid addition salts, the wavy line indicating the cis form, trans form or cis trans forms having antibiotic properties.

  合成新的同分异构体和3-氨基-2-氧代氮杂环-1-磺酸的光学异构体的方法，其中R从氢、1至12碳原子的线性或支链可选取代烷基和2至12碳原子的可选取代烯基和炔基组成的群中选择，R.sub.1为--(CH.sub.2).sub.n --X，n为1至4之间的整数，X从卤素、--CN、--OR'、--SR.sub.1"、叠氮基、硫氰酸基、异硫氰酸基和##STR2##中选择，其中##STR2##从氢和1至4碳原子的烷基组成的群中选择，R"从氢、1至4碳原子的烷基和杂环组成的群中选择，R'和R"分别从氢和1至4碳原子的烷基组成的群中选择，并与它们连接的氮一起形成一个杂环，A.sup.1从氢和金属阳离子及其无毒、药学上可接受的酸盐中选择，波浪线表示具有抗生素性质的顺式形式、反式形式或顺反式形式。
• AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Chao Qi

  公开号：US20130303533A1

  公开（公告）日：2013-11-14

  Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗JAK激酶介导的疾病，包括JAK2激酶、JAK3激酶或TYK2激酶介导的疾病的咪唑吡啶和咪唑嘧啶化合物。还提供了包含这些化合物的药物组合物和使用这些化合物和组合物的方法。
• Inhibitors of bruton's tyrosine kinase
  申请人：Dewdney Nolan James

  公开号：US08426441B2

  公开（公告）日：2013-04-23

  This application discloses novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives according to Formulae I-VI: wherein R, R′, R″, Q, X, and Y are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-VI and at least one carrier, diluent or excipient.

  本申请披露了新的咪唑[1,2-a]吡啶和咪唑[1,2-b]吡嗪衍生物，其按照式I-VI定义：其中R、R'、R"、Q、X和Y如本文所述，可以抑制Btk。本文披露的化合物有助于调节Btk的活性并治疗与过度Btk活性相关的疾病。这些化合物还有助于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，例如类风湿性关节炎。本申请还披露了含有式I-VI化合物和至少一种载体、稀释剂或赋形剂的组合物。